Excited to have Dr. Ines Sanchez-Rivera (@TexasOncology) as chair of BTF's 2024 Updates on Hematology and Oncology, El Paso! 🗓️ July 20, 2024 📍 Marriott El Paso REGISTER HERE ➡️ education.binayfoundation.org/content/btfs-2… #CME #ASCO #ASCO24 #oncology #Hematology #cancer #cancercare

@SarahMBelcher It was so amazing to see you again! Hope to run into you at #ASCO24!

Excited for #ASCO24 just 4 weeks away! Eager to see everyone and learn about the latest scientific advancements in #oncology. Stay tuned for valuable insights! #cancerresearch

📪When you see this in your mailbox, start getting ready to go to @ASCO #ASCO24⭐️💫☄️ ⭐️⭐️⭐️Excited to see all friends and experts⭐️⭐️⭐️ ...and present our data about unclassified #renal #cell #cancer 🧬Applying genomic analysis to refine unclassified renal cell carcinoma.🧬…

June 3rd, 8am #ASCO24 @ASCO - upper GI and hepatobiliary cancers @LizzySmyth1 @DrSRBrown @curecc @KlempnerSam - Getting Molecular Profiling Incorporated Into the Standard of Care in the Community Setting | ASCO Daily News dailynews.ascopubs.org/do/getting-mol…

Reunion in Chicago for #HOPlive24 counting down the days to #ASCO24. Insightful fellow panel on mentorship, educations, career decisions & the job search

keyboard_arrow_left Previous keyboard_arrow_right Next

Countdown to @ASCO 2024! 🤩 LARVOL CLIN highlights the top trials, as discussed by over 2500 top oncologists. Don’t miss the key findings that are shaping the future of oncology. For more pre-ASCO 2024 insights visit: bit.ly/4aZuU40 #ASCO24 #LARVOL #Oncology

#ASCO24! Dive into the latest advances in the utility of #PIK3CA/#TP53 mutation for stratifying patients with HR+/HER2- metastatic breast cancer for optimal first-line therapy. Dr. Federico Rojo’s poster #1029: Hall A; June 2; 9:00 AM – 12:00 PM CDT #CDK4/6 #liquidbiopsy

Treatment landscape for resectable NSCLS is quickly changing. Discussion/group effort by led @ASridharMD @IvyLorena_Md @ArpanAshokPatel to reiterate the current SoC! @FordePatrick thank you for ICER table! 🙏🏽🙏🏽 #lcsm #ASCODailyNews @ASCO #OncTwitter #ASCO24 #MedTwitter

keyboard_arrow_left Previous keyboard_arrow_right Next

Join #BreastCancer expert Drs. Komal Jhaveri, (@jhaveri_komal) Javier Cortes, (@JavierCortesMD), Prof. Giuseppe Curigliano, (@curijoey) & Ian Krop, MD, PhD on 5/31 at 6:30 PM CDT for a #MedEd Event! Produced with @LivingBeyondBC & @GRASPtweets: bit.ly/2024MBCT #ASCO24

The trouble is that the next investor interface, before #ASCO24, will be the usual quarterly focus on what Lanfear and his team HAVEN'T done. Last quarterly, I expected lotsa PR bullets with at least one being INOVIO-like. Got nada. Retire, jackass!

UBC is uniting evidence and access across the product lifecycle for oncology. Meet our team at ASCO 2024 to learn about our comprehensive, consultative, patient-centric solutions: hubs.li/Q02vSxnd0 #PatientsFirst #ASCO24 #Oncology #Pharma

So what's in store for lung cancer at #asco24 @ASCO Apart from Laura and Adriatic which are plenary sessions We have some interesting data coming up #LCSM 1 - will Sacituzumab Govitecan be better than Docetaxel in second line NSCLC? EVOKE -01 study . 2 - will addition of…

keyboard_arrow_left Previous keyboard_arrow_right Next

Dr Amol Akhade @SuyogCancer

a week ago

So what's in store for lung cancer at #asco24 @ASCO Apart from Laura and Adriatic which are plenary sessions We have some interesting data coming up #LCSM 1 - will Sacituzumab Govitecan be better than Docetaxel in second line NSCLC? EVOKE -01 study . 2 - will addition of… https://t.co/AIjjkqtc9F

keyboard_arrow_left Previous keyboard_arrow_right Next

8 12 43 13K 5

Download Image

Calling #oncologists: Join us for Sylvester's #MiamiNights during the @ASCO Annual Meeting at 8 p.m., Sunday, June 2. Register now ▶️ loom.ly/hAFlmAg, for an unforgettable experience. See you there! #ASCO24

Nice to see a little strength, with a marked easing of 50k block dumping at market..... $CHRS headed to #ASCO24 and CCR8 phase I peek. Double header, also anti-CCR8 plus loqtori from #LaNova, LM-108 with both breakthrough and orphan FDA status.... with luck, coming to U.S.